Life Science Investing Journey Medical Corporation Reports Combined Emrosi Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
Life Science Investing Journey Medical Corporation to Participate in October 2025 Investor Conferences
Life Science Investing Journey Medical Corporation to Participate in September 2025 Investor Conferences
Forte Minerals Closes a Second C$5.7 Million Strategic Investment and Additional Participation from Existing Strategic Investor
LaFleur Minerals Provides Update on Confirmation Drilling for PEA at Swanson Gold Deposit and Beacon Gold Mill, Val-d'Or, Québec
Cartier Cuts 111.5 g/t Au over 2.0 m at Contact ; Confirms Multiple High-Grade Gold Zones; Extends Drilling at Surface
